Waldencast plc Class A Ordinary Share (WALD)

FairStock Score: 49/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Waldencast owns beauty and wellness brands, chiefly Obagi Medical and Milk Makeup, in a consumer-defensive category. That can be a good place to hunt, but the numbers are not yet those of a durable compounder. The filed figures show no revenue, so I cannot assess top-line growth. They do show uneven profits: in fiscal Q2 2021, the quarter ended 2021-06-30, net income was -$1.6M; in fiscal Q3 2021, the quarter ended 2021-09-30, net income was $7.8M; and in fiscal Q1 2022, the quarter ended 2022-03-31, net income was $3.0M. But for fiscal 2021, the year ended 2021-12-31, net income was -$14.4M. Diluted EPS in fiscal Q1 2021, the quarter ended 2021-03-31, was -$0.13. At the close on 2026-10-13, the stock was $0.85, with a market cap of $101.6M. FairStock's calculated P/B is 0.22, which might suggest asset value, but FairStock's calculated P/E is -0.42 and the stated EPS is -$2.01, so there are no positive earnings to capitalize. FairStock's calculated ROE is -40.33% and ROCE is -4.72%. FairStock's Piotroski F-Score is 2/9 and Altman Z-Score is -0.64, both pointing to financial weakness. Debt-to-equity of 0.30 is not terrifying, but losses erode equity. The Lynch category is none because there is only one year of filed results, not three. A low price versus book can be a margin of safety only if the assets are real and earning power returns. Here, I see a speculative turnaround, not a proven bargain.

In plain English: Waldencast sells beauty and personal-care products through brands such as Obagi Medical and Milk Makeup. The business looks weak: it lost $14.4 million in fiscal 2021 and has not shown steady profits in the filed figures. The share price is very low compared with the company’s accounting value, but without reliable earnings and with weak financial-health scores, it looks more like a risky turnaround than a clear bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2022 10-Q (period ended 2022-03-31) · fiscal Q3 2021 10-Q (period ended 2021-09-30) · fiscal Q2 2021 10-Q (period ended 2021-06-30) · fiscal Q1 2021 10-Q (period ended 2021-03-31) · FY2021 10-K (period ended 2021-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer